SOPHiA GENETICS SA (SOPH) - Forward P/S Multiple

Public company logo of SOPHiA GENETICS S.A. (SOPH)

SOPHiA GENETICS SA (SOPH) utilizes an elastic SaaS infrastructure to support the expansion of computing power for its multimodal AI cancer-fighting platform. The company's forward P/S ratio clearly demonstrates the market value's reaction to liquidity, with 7.40 representing the latest level. The development of the cloud ecosystem is driven by a staff of leading bioinformaticians attracted by flexible scheduling and an equity option system.

Sophia Genetics - SOPH Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

SOPH (sophiagenetics.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes SOPHiA GENETICS|SOPH - Fair Value Consensus
- market capitalization indicators:
Market Capitalization SOPH|SOPH - Full Takeover Company Value
- issuer book value statistics:
Book Value per Share SOPHiA GENETICS SA|SOPH - Total Stockholders' Equity|Market Value to Book Value Ratio sophiagenetics.com|SOPH - Total Business Assets
- debt and liquidity details:
Total Debt to Capital SOPHiA GENETICS SA|SOPH - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio SOPHiA GENETICS|SOPH - Company Cumulative Indebtedness|Debts to Book Capitalization SOPH|SOPH - Long-Term Debt Volume|Company Short-Term Debts SOPHiA GENETICS SA|Quick Liquidity sophiagenetics.com
- financial results and valuation multiples details:
SOPH - Net Financial Result|Future Profit SOPHiA GENETICS SA|SOPH - Company Value to Net Income|Future Price to Earnings SOPHiA GENETICS|SOPH - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple SOPH|SOPH - Operating profit EBITDA|Earnings per share for the last twelve months SOPHiA GENETICS SA|SOPH - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months sophiagenetics.com|SOPH - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year SOPHiA GENETICS SA
- revenue and sales details:
SOPH - Company Annual Revenue|Projected Sales Volume SOPHiA GENETICS|SOPH - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple SOPH
General company analysis:SOPHiA GENETICS S.A. SOPH
Product sample of Sophia Genetics

To objectively assess the operational success of SOPHiA GENETICS SA (SOPH), investors must understand the extent to which the market is willing to pay a premium for the scaling of a cloud-based genome analysis platform with a global subscription base. By analyzing the forward price-to-sales ratio, you can see the relationship between current market capitalization and projected sales, which allows for a determination of the level of optimism priced in and the risks of a correction should expansion slow.

Analysis of competing companies

Veeva - Forward Price-to-Revenue Multiple|Forward Price to Sales DOCS|HealthEquity Corp - Forward P/S Multiple|Projected Price to Revenue Waystar Corp (WAY)|CRVL: Forward P/S Multiple|Market Cap to Future Revenue Ratio priviahealth.com (PRVA)|Price-to-Projected Revenue Ratio Huron|Market Cap to Projected Revenue CERT (Certara Inc)|Forward P/S Multiple OMCL|GDRX - Market Cap to Future Revenue Ratio|Schrodinger, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio PHR (phreesia.com)|Omada Health - Forward P/S Multiple|Market Cap to Expected Sales Ratio Evolent Health Inc EVH|HSTM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Definitive Corp|Price-to-Projected Revenue Ratio Consensus Cloud Solutions|agilonhealth.com (AGL) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ABSI (Absci Corporation)|SY (So-Young International Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio National Research Corporation NRC|Market Cap to Expected Sales Ratio USA Mobility (SPOK)|OptimizeRx Corporation - Forward P/S Multiple|TBRG - Forward P/S Multiple|Simulations Plus (SLP) - Price-to-Projected Revenue Ratio|HCAT - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CareCloud Inc.|Market Cap to Future Revenue Ratio Research Solutions Inc. RSSS|Price-to-Projected Revenue Ratio DLH Holdings Corp. (DLHC)|ONMD: Future Price to Revenue|Forward P/S Multiple SCNX (Scienture)|Forward Price to Sales HCTI|iSpecimen Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Bullfrog AI Holdings BFRG|WORX (SCWorx Corp.) - Forward Price-to-Revenue Multiple|MSPR: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple ICCT|MEDS: Forward Price to Sales|Price-to-Projected Revenue Ratio Orgenesis Corp (ORGS)|Forward Price-to-Revenue Multiple r1rcm.com RCM|Forward P/S Multiple SHCR (Sharecare, Inc.)|streamlinehealth.net (STRM) - Market Cap to Future Revenue Ratio|Syra Health - Forward P/S Multiple|AMEH (Apollo Medical Holdings) - Market Cap to Projected Revenue|Model N Corp (MODN) - Price-to-Projected Revenue Ratio|NXGN - Market Cap to Expected Sales Ratio